**Core tip:** We found that (1) *HULC* expression was higher in serum exosomes of patients with HCC than in those of healthy controls, and higher in liver cancer tissues than in tumor adjacent tissues; (2) *HULC* expression in serum exosomes and liver cancer tissues were correlated with the TNM classification, and *HULC* expression in tissues was correlated with that in serum exosomes; (3) Increased *HULC* expression was associated with increased proliferation and invasion and reduced apoptosis of HCC cells; and (4) *HULC* repressed *miR-372-3p* expression, and *miR-372-3p* could directly bind both *HULC* and *Rab11a*. Furthermore, the *HULC/ miR-372-3p /Rab11a* axis promoted the secretion of exosomes from HCC cells.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is a malignant tumor with high mortality, and more than 700000 patients with HCC die every year worldwide. Tumor invasion, metastasis, and recurrence are the main causes of death in these patients\[[@B1]\]. Despite advances in the understanding of the molecular mechanisms underlying HCC and improved therapeutic methods to treat this disease, the 5-year overall survival (OS) for patients with HCC is still unsatisfactory\[[@B2]\].

Long noncoding RNAs (lncRNAs) are transcribed RNAs that regulate gene expression through various mechanisms. LncRNAs exert vital roles in many processes such as transcriptional control, posttranscriptional regulation, and epigenetic regulation\[[@B3]\]. In recent years, it has been demonstrated that several lncRNAs play an important role in the progression of HCC\[[@B4]\]. One of these lncRNAs is *HULC*, located on chromosome 6p24.3, which was found to be highly expressed in HCC tissue by Panzitt in 2007\[[@B5]\]. *HULC* transcription produces an RNA of approximately 500 nt that is located in the cytoplasm and participates in the development of HCC\[[@B6]\]; it acts as a competitive endogenous RNA (ceRNA), which regulates mRNA through competitive miRNA sharing. For example, *HULC*, in combination with *miR-15a*, inhibits *PTEN* expression and participates in autophagy to promote the progression of HCC\[[@B7]\]. *Via* sequestrating *miR-124*, *HULC* participates in endothelial cell angiogenesis\[[@B8]\]. However, the mechanism of *HULC*-mediated invasion and metastasis of HCC remains unclear.

In recent years, exosomes have become a research hotspot, and they have been found to be closely related to tumor progression\[[@B9]\]. Exosomes are membranous structures derived from cells that play various roles in normal physiology\[[@B10]\]. In cancer, exosomes have been shown to contribute to essential cancer-related processes such as sustaining the proliferative signalling, evading growth suppression, resisting cell death, enabling replicative immortality, inducing angiogenesis, promoting genome instability and mutations, increasing tumor-promoting inflammation, and especially activating invasion and metastasis. In the tumor, exosomes participate in basic cancer-related processes such as promoting cancer cell proliferation, reducing apoptosis, achieving replication immortality, inducing angiogenesis, promoting genomic instability and mutations, increasing tumors and promoting inflammation, and especially activating tumors. For example, exosomal *miR-335* could be a novel therapeutic strategy for HCC\[[@B11]\]. Tumor-derived exosomes could elicit tumor suppression in murine HCC models and humans *in vivo*\[[@B12]\]. Additionally, exosomes are frequently released by tumor cells and may facilitate the communication between the primary tumor and its local microenvironment\[[@B13]\]. The link between *HULC* and exosomes in tumor genesis and development has not been clarified to date.

In this study, we investigated the expression of *HULC* in serum-derived exosomes and hepatic tissues, analysed the correlation between *HULC* expression and other RNAs, and demonstrated the mechanism of action of *HULC* in HCC. Increased *HULC* expression was associated with increased proliferation and invasion, and reduced apoptosis of HCC cells. *HULC* was found to function as a ceRNA of *miR-372-3p*, which, in turn, inhibits the expression of *Rab11a*. Rab proteins are key regulators of intracellular membrane trafficking, and Rab11a has been reported to promote exosome secretion\[[@B14],[@B15]\]. Thus, *HULC* induces exosome secretion and contributes to tumor growth and metastasis.

MATERIALS AND METHODS
=====================

Subjects
--------

Serum samples and tissues (*n =* 30) and paired adjacent liver tissues (*n =* 30) were obtained from patients with HCC who underwent surgery at the Tianjin First Central Hospital (China) from January to August 2017. Normal human serum was taken from patients undergoing a physical examination at the Tianjin First Central Hospital (China). All our patients had hepatitis B virus associated cancer with cirrhosis. The average age of the patients was 53.9 ± 16.2 years. Patient clinical data are shown in Table [1](#T1){ref-type="table"}. Tumor differentiation and TNM stage were assessed based on the WHO grading system. Each HCC case was confirmed by histopathological diagnosis. Blood samples from the patients were taken one week before surgery. Tissue samples were taken from the resected HCC tissues and tumor-adjacent liver tissues (histopathological diagnosis confirmed that the tumor had not invaded the adjacent tissues). The serum and tissue samples were immediately stored at -80 °C before use. This study was approved by the Tianjin First Central Hospital Medical Ethics Committee, and all patients provided written informed consent for the use of their samples for clinical research.

###### 

Relationship between expression of long non-coding RNA highly up-regulated in liver cancer and clinicopathological factors in patients with hepatocellular carcinoma

  **Clinicopathological factor**   **Number of patients** **(*n* = 30)**   ***HULC* in serum exosomes**   **χ^2^**   ***P*-value**   ***HULC in* HCC tissue**   **χ^2^**   ***P*-value**           
  -------------------------------- --------------------------------------- ------------------------------ ---------- --------------- -------------------------- ---------- --------------- ------- -------
  Age (yr)                                                                                                           0.391           0.532                                                 0.382   0.497
  ≤ 55                             18                                      11                             7                                                     12         8                       
  \> 55                            12                                      7                              5                                                     5          5                       
  sex                                                                                                                0.370           0.492                                                 0.365   0.592
  Female                           21                                      11                             7                                                     13         8                       
  Male                             9                                       6                              6                                                     4          5                       
  **Tumor size (cm)**                                                                                                2.323           0.124                                                 2.225   0.126
  ≤ 5                              10                                      4                              6                                                     5          5                       
  \> 5                             20                                      11                             9                                                     10         10                      
  **Tumor differentiation**                                                                                          2.224           0.115                                                 2.356   0.098
  Well/moderate                    21                                      12                             9                                                     11         8                       
  Poor                             9                                       5                              4                                                     6          5                       
  **Clinical stage (TNM)**                                                                                           4.812           0.032                                                 4.924   0.026
  I-II                             10                                      5                              5                                                     4          6                       
  III-IV                           20                                      11                             9                                                     12         8                       

*HULC*: Highly upregulated in liver cancer; HCC: Hepatocellular carcinoma; TNM: Tumor-node-metastasis.

The inclusion criteria were: (1) Patients with complete clinical data; and (2) Patients had not received chemotherapy, radiotherapy, or immunotherapy before surgery. The exclusion criteria were: (1) Lack of clinical data; (2) Area of necrosis in the tumor tissue \> 60%; and (3) Presence of additional malignant tumors.

Cell culture
------------

Human HCC cell lines (HepG2 and SMMC7721) and a normal hepatic cell line (LO2) were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM or RPMI-1640 (GIBCO, Grand Island, NY, United States) containing 10% foetal bovine serum (FBS; BioWest, Nuaille, France), and 1% bivalent antibiotics (Hyclone, South Logan, UT, United States). Cells were incubated at 37 °C with 5% CO~2~.

Exosome extract
---------------

Exosomes were isolated from HCC cells as follows. Exosome-depleted FBS was obtained by ultracentrifugation at 110000 *g* (CP80MX; HITACHI, Japan) for 16 h and used for culturing HCC cells. HCC cell culture medium supernatants were collected after incubation for 48 h, and then centrifuged at 10000 *g* for 40 min to remove HCC cell debris. Supernatants were filtrated through a 0.22 μm-pore filter (Millipore). The ExoQuick solution (EXOTC10A-1, System Biosciences, Mountain View, United States) was added to the filtered solution at a 1:5 ratio. The mixed solution was stored at 4 °C for 12 h, and then centrifuged at 1500 *g* for 30 min. The supernatants were discarded, and the precipitate (containing the exosomes) was dissolved in phosphate buffered saline (PBS).

Exosomes were isolated from patients' serum as follows. The serum was filtrated through a 0.22 μm-pore filter (Millipore). The ExoQuick solution (EXOQ5A-1, System Biosciences, Mountain View, United States) was added to the filtered solution at a 1:4 ratio. The mixed solution was stored at 4 °C for 12 h, and then centrifuged at 1500 *g* for 30 min. The supernatants were discarded, and the precipitate (containing the exosomes) was dissolved in PBS.

Transfection
------------

*HULC* (*HULC* over-expression plasmid), *HULC*-NC (*HULC* over-expression normal control plasmid), *HULC*-siRNA (*HULC* low-expression plasmid), *HULC*-siRNA-NC (*HULC* low-expression control plasmid), miRNA-*372-3p* (miRNA-*372-3p* over-expression plasmid), miRNA-*372-3p* inhibitor, WT-*HULC* (*HULC* wild type luciferase reporter plasmid), MUT-*HULC* (*HULC* mutant luciferase reporter plasmid), WT-*Rab11a* (*Rab11a* wild type luciferase reporter plasmid), and MUT-*Rab11a* (*Rab11a* mutant luciferase reporter plasmids) (Genechem, Shanghai, China) were used for transfection experiments. HepG2 and SMMC7721 cells were seeded in 6-well plates and transfected with *HULC* inhibitors or plasmids causing *HULC* overexpression, using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The transfected cells were incubated for 48 h before analysis.

Western blot analysis
---------------------

Protein samples were collected from cells or exosomes in RIPA lysis buffer (Solarbio, Beijing, China). The processed protein samples were separated by 10% SDS--polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 0.22 μm PVDF membranes (Millipore), and incubated with primary antibodies against CD63, TSG101, Rab11a, and GAPDH (Abcam, Cambridge, MA, United States) at 4 °C. The secondary antibody was goat anti-rabbit antibody (Abcam, Cambridge, MA, United States) and incubation was performed at 24 °C. Chemiluminescence reagent (Millipore) was used to detect the proteins.

Nanoparticle tracking analysis (NTA)
------------------------------------

NTA with a ZetaView PMX (Particle Metrix, Dusseldorf, Germany) was used to measure concentration, mean particle size, and distribution of exosomes. Exosomes were resuspended in 0.05 × PBS (filtered through a 0.22 μm-pore filter) and added to the instrument. The same parameters were used for size and concentration measurements. Data were analysed using the software ZetaView 8.02.28 and Microsoft Excel 2016 (Microsoft, Seattle, WA, United States).

Transmission electron microscopy
--------------------------------

The purified exosomes were fixed with 1% glutaraldehyde in PBS. A drop of the suspension (approximately 20 μL) was pipetted onto formvar/carbon-coated grids and stained with aqueous phosphotungstic acid for 1 min. The morphology of isolated exosomes was identified using a transmission electron microscope (HT7800, Hitachi, Japan).

Quantitative PCR
----------------

Total RNA was extracted from HCC tissues and cells using Trizol reagent (Invitrogen, Carlsbad, CA, United States) and total RNA was extracted from exosomes using the SeraMir Exosome RNA Purification Kit (System Biosciences, Mountain View, United States) following the manufacturer's instructions. After determining the concentration, degree, and purity of RNA, cDNA was synthesised using a reverse transcription kit (Takara Biotechnology, Japan) and PCR was performed with a commercial kit (Takara Biotechnology). With GAPDH and U6 as references, the expression levels of HULC, miRNA-372-3p, and Rab11a were calculated using relative quantitative analysis. The relative standard curve method (2^-△△CT^) was used to determine the relative RNA expression in cells and -△CT was used to determine the relative RNA expression in HCC tissues and serum exosomes. The primers used for quantitative PCR (qPCR) are shown in Table [2](#T2){ref-type="table"}.

###### 

Primers used for quantitative PCR

  **Gene**                                                 **Primer sequence**
  -------------------------------------------------------- ------------------------------------------------------
  *HULC*                                                   Forward: 5'-GCAAGCCAGGAAGAGTCGTC-3\'
  Reverse: 5'-GCTGTGCTTAGTTTATTGCCAGG-3\'                  
  *GAPDH*                                                  Forward: 5\'-GTCAACGGATTTGGTCTGTATT-3\'
  Reverse: 5\'-AGTCTTCTGGGTGGCAGTGAT-3\'                   
  miRNA-*372-3p*                                           Forward: 5\'-CAACAGAAGGCTCGAGCAACCTGCGGAGAAGATAC-3\'
  Reverse: 5\'-TTCTGATCAGGATCCCATTACAGCCAGACGCTGTAAG-3\'   
  *U6*                                                     Forward: 5\'-GCGCGTCGTGAAGCGTTC-3\'
  Reverse: 5\'-GTGCAGGGTCCGAGGT-3\'                        
  *Rab11a*                                                 Forward: 5\'-ACATCAGCATATTATCGTGGAGC-3\'
  Reverse: 5\'-GGAACTGCCCTGAGATGACG-3\'                    

*HULC*: Highly upregulated in liver cancer.

Dual-luciferase reporter assay
------------------------------

*HULC* could specifically bind to *miR-372-3p*, acting as a \"microRNA sponge\"\[[@B16],[@B17]\]. At the same time, *miR-372-3p* was predicted to regulate *Rab11a* expression using TargetScan (<http://www.targetscan.org/>) and starBase (<http://starbase.sysu.edu.cn/>). *HULC* and *Rab11a* 3′-UTR double luciferase recombinant plasmids (Genechem, Shanghai, China) were constructed and transfected into HCC cells. Luciferase assays were performed using a luciferase reporter assay kit (Genecopoeia) according to the manufacturer's recommendations. Before detection, HCC cells were washed 2-3 times with PBS, and 150 μL of fresh passive cell lysate was added into each well (24-well plates) to lyse the cells. The supernatant was centrifuged at 13000 *g* for 1 min, and 20 μL of the supernatant was transferred to 96-well plates. Then, 100 μL of LAR II was added to detect the firefly luciferase activity. The Stop&Glo reagent (100 mL) was used to detect the fluorescence of the *Renilla* luciferase. Luciferase was measured using a microplate reader, with 1-2 s delay and 5-10 s readings for measurement. The final luciferase activity is expressed as the ratio of luciferase activity of firefly/luciferase activity of *Renilla*.

Cell counting kit-8 (CCK8)
--------------------------

Cells (50000 cells per well) were cultured overnight in a 96-well plate. At 0, 24, 36, 48, and 72 h, respectively, 100 μL of CCK8 solution (BOSTER, Wuhan, China) was added. The assay was performed according to the manufacturer's recommendations. A microplate reader (Bio Tek Synergy2, United States) was used to measure the absorbance at 450 nm.

Transwell assay
---------------

Cells were seeded in the upper chamber of Matrigel-coated Transwells (BD Bioscience, CA, United States). Serum-free medium was added to the upper chamber, and medium with 10% FBS was added into the lower chamber. Cells were incubated for 24 h; the non-migrating or non-invading cells were removed, and the remaining cells (on the bottom of the filters) were fixed using methanol and stained with crystal violet. Five random fields were chosen and counted per well using a microscope (×100), (Olympus, Tokyo, Japan).

TUNEL assay
-----------

Apoptosis was detected using TUNEL assay. Cells were fixed using 4% paraformaldehyde for 30 min, and the assay was carried out using a TUNEL kit (Roche, Basel, Switzerland) according to the manufacturers' recommendations. Nuclei were stained with DAPI. Apoptotic cells with green nuclear staining were observed. Five random fields were chosen and counted per well by using a microscope (×100). The number of apoptotic cells was counted, and the apoptotic rate (%) was calculated as (apoptotic cell count/total cell number) × 100%.

Statistical analysis
--------------------

The SPSS statistical software version 20.0 was used for statistical analyses. The data, expressed as the mean ± SD, were analysed using one-way ANOVA. Count data, expressed as percentages (%), were analysed using the χ^2^ tests. *P-*values \< 0.05 were considered statistically significant.

RESULTS
=======

Exosome extraction from HCC cells and serum of patients with HCC
----------------------------------------------------------------

Exosomes were successfully extracted from the serum of patients with HCC and HCC cell medium (Figure [1](#F1){ref-type="fig"}). First, we examined the shape and size of the exosomes isolated from HCC serum (Figure [1A](#F1){ref-type="fig"}) and the culture medium of HepG2 or SMMC7721 cells (Figure [1B](#F1){ref-type="fig"}) by transmission electron microscopy. The exosomes were homogeneous in shape and size, and the vesicles had the characteristic appearance of exosomes with a membrane-capsulated spherical shape. The median size of the vesicles, calculated by NTA, was 110.2 nm and 106.9 nm in HCC serum (Figure [1C](#F1){ref-type="fig"}) and the culture medium of HepG2 or SMMC7721 cells (Figure [1D](#F1){ref-type="fig"}), respectively, similar to the reported size of exosomes (30--120 nm)\[[@B18]\]. Additionally, Western blot assays showed that the TSG101 and CD63 exosome markers were part of the exosome cargo (Figure [1E, 1F](#F1){ref-type="fig"}), confirming that the isolated vesicles were indeed exosomes.

![Identification of the exosomes. A: Transmission electronc microscopy (TEM) of exosomes extracted from the serum of patients with hepatocellular carcinoma (HCC); B: TEM of exosomes isolated from HCC cell medium; C: Western blot analysis of exosomal markers (CD63 and TSG101) in HCC serum; D: Western blot analysis of exosomal markers (CD63 and TSG101) in HCC cell medium; E: Nanoparticle tracking analysis (NTA) for detection of exosomes extracted from the HCC serum; F: NTA detection of exosomes extracted from HCC cell medium.](WJG-25-5283-g001){#F1}

HULC is upregulated in liver cancer serum-derived exosomes, hepatic tissues, and HCC cells
------------------------------------------------------------------------------------------

The baseline characteristics of the 30 patients (9 men and 21 women) enrolled in this study are summarised in Table [1](#T1){ref-type="table"}. The average age was 53.9 ± 16.2 years. The expression of *HULC* in the serum exosomes of patients with HCC was higher than that in exosomes from healthy subjects (*P* \< 0.05; Figure [2A](#F2){ref-type="fig"}). *HULC* levels in liver cancer tissues were higher than those in adjacent tissues (*P* \< 0.05; Figure [2B](#F2){ref-type="fig"}). The expression of *HULC* in tissues correlated with that in exosomes (*r* = 0.633, *P* \< 0.05; Figure [2C](#F2){ref-type="fig"}). Additionally, the expression of *HULC* in serum exosomes correlated with the TNM stage of the patients (*P* \< 0.05; Table [1](#T1){ref-type="table"}). Finally, *HULC* was upregulated in HepG2 and SMMC7721 cells (Figure [3A](#F3){ref-type="fig"}).

![Detection of long non-coding RNA highly up-regulated in liver cancer in hepatocellular carcinoma. A: Expression of *HULC* in the serum exosomes of patients with HCC; B: Expression of *HULC* in liver cancer tissues; C: Correlation between *HULC* expression in HCC serum exosomes and tissue. Error bars stand for the mean ± SD of at least triplicate experiments. *HULC*: Highly upregulated in liver cancer; HCC: Hepatocellular carcinoma.](WJG-25-5283-g002){#F2}

![Detection of long non-coding RNA highly up-regulated in liver cancer in hepatocellular carcinoma cells. A:Expression of *HULC* in HepG2, SMMC7721, and LO2 cells; B: Expression of *HULC* in HepG2 transfected with *HULC* inhibitors or plasmids causing *HULC* overexpression; C: Expression of *HULC* in SMMC7721 transfected with *HULC* inhibitors or plasmids causing *HULC* overexpression. Error bars stand for the mean ± SD of at least triplicate experiments. ^a^*P* \< 0.05 *vs* LO2 group; ^b^*P* \< 0.05 *vs* LO2 group; ^c^*P* \< 0.01 *vs* NC group; ^d^*P* \< 0.01 *vs HULC*-NC group; ^e^*P* \< 0.05 *vs* NC group; ^f^*P* \< 0.05 *vs HULC*-siRNA-NC group. *HULC*: Highly upregulated in liver cancer; NC: Normal control group; *HULC*: *HULC* over-expression plasmid group; *HULC*-NC: *HULC* over-expression normal control plasmid group; *HULC*-siRNA: *HULC* low-expression plasmid group; *HULC*-siRNA-NC: *HULC* low-expression control plasmid group.](WJG-25-5283-g003){#F3}

HULC induces HCC cell proliferation and invasion and inhibits apoptosis
-----------------------------------------------------------------------

After transfection of *HULC* over-expression and inhibiting plasmids into HCC cells, the expression of *HULC* changed significantly (Figure [3B, 3C](#F3){ref-type="fig"}). To explore the role of *HULC* in HCC cells, we performed CCK8 assays. We observed that *HULC* upregulation was associated with the growth of HepG2 and SMMC7721 cells (Figure [4A](#F4){ref-type="fig"}). Next, TUNEL assays showed that apoptosis was significantly inhibited by *HULC* (Figure [4B, 4C](#F4){ref-type="fig"}). Finally, we tested the effect of HULC on the invasion capabilities of HCC cells using Transwell assays, which showed that HULC induced the invasion of HCC cells (Figure [4D, 4E](#F4){ref-type="fig"}). These results suggest that *HULC* remarkably promoted HCC development.

![Long non-coding RNA highly up-regulated in liver cancer induces hepatocellular carcinoma cell proliferation and invasion and inhibits apoptosis *in vitro*. A: Proliferation of hepatocellular carcinoma (HCC) cells transfected with *HULC* inhibitors or plasmids causing *HULC* overexpression; B: Apoptotic pictures of HCC cells (×100). The blue fluorescence is DAPI nuclear staining and green fluorescence is the apoptotic cell. The index of apoptosis is the number of apoptotic cells/total number of visual field × 100%; C: Column chart of index of apoptosis in different groups; D: Effect of *HULC* on invasion of HCC cells evaluated bTranswell assay (×100); E: Column chart of number of invasive HCC cells in different groups. Error bars stand for the mean ± SD of at least triplicate experiments. ^a^*P* \< 0.05 *vs HULC*-NC 24 h group; ^b^*P* \< 0.05 *vs HULC*-NC 36 h group; ^c^*P* \< 0.05 *vs HULC*-NC 48 h group; ^d^*P* \< 0.05 *vs HULC*-NC 72 h group; ^e^*P* \< 0.05 *vs* NC group; ^f^*P* \< 0.05 *vs HULC*-NC group; ^g^*P* \< 0.01 *vs* NC group; ^h^*P* \< 0.01 *vs HULC*-siRNA-NC group; ^i^*P* \< 0.05 *vs* NC group; ^j^*P* \< 0.05 *vs HULC*-NC group; ^k^*P* \< 0.05 *vs* NC group; ^l^*P* \< 0.05 *vs HULC*-siRNA-NC group. *HULC*: Highly upregulated in liver cancer; NC: Normal control group; *HULC*: *HULC* over-expression plasmid group; *HULC*-NC: *HULC* over-expression normal control plasmid group; *HULC*-siRNA: *HULC* low-expression plasmid group; *HULC*-siRNA-NC: *HULC* low-expression control plasmid group.](WJG-25-5283-g004){#F4}

HULC reduces the expression of miR-372-3p by sponging it
--------------------------------------------------------

The relationship between lncRNA *HULC* and *miR-372-3p* has been reported in many studies\[[@B16],[@B17]\]. Therefore, we identified the binding sites between *miR-372-3p* and *HULC* (Figure [5A](#F5){ref-type="fig"}). To confirm the direct interaction between *miR-372-3p* and *HULC*, we generated luciferase reporter plasmids with the wild type or mutated *HULC* sequence (Figure [5A](#F5){ref-type="fig"}). A decreased reporter activity was observed when wild type *HULC* and *miR-372-3p* mimics were co-transfected into HCC cells (Figure [5B](#F5){ref-type="fig"}). To investigate whether *miR-372-3p* is regulated by *HULC in vitro*, we overexpressed *HULC* in HepG2 and SMMC7721 cells and measured *miR-372-3p* expression (Figure [5C](#F5){ref-type="fig"}). We found that *miR-372-3p* levels decreased after *HULC* upregulation (Figure [5C](#F5){ref-type="fig"}), indicating a negative correlation between *miR-372-3p* and *HULC*. These results showed that *miR-372-3p* is a direct target of *HULC* in HCC cells.

![Long non-coding RNA highly up-regulated in liver cancer mediates secretion of exosomes from hepatocellular carcinoma cells *via miR-372-3p* /*Rab11a*. A: Sequence of binding sites between *HULC* and *miR-372-3p*; B: Dual-luciferase reporter assay for *miR-372-3p* and *HULC*; C: Relative expression of *miR-372-3p* after HCC cells were transfected with *HULC* inhibitors or plasmids causing *HULC* overexpression; D: Sequence of binding sites with *Rab11a* and *miR-372-3p*; E: Dual-luciferase reporter assay for miR-*372-3p* and *Rab11a*; F: Relative expression of *Rab11a* after HCC cells were transfected with *miR-372-3p*-siRNA or plasmids causing *miR-372-3p* overexpression. Error bars stand for the mean ± SD of at least triplicate experiments. ^a^*P* \< 0.05 *vs* WT-*HULC*-NC group; ^b^*P* \< 0.05 *vs* NC group; ^c^*P* \< 0.01 *vs* NC group; ^d^*P* \< 0.05 *vs* WT-*Rab11a* -NC group; ^e^*P* \< 0.05 *vs* NC group; ^f^*P* \< 0.01 *vs* NC group. *HULC*: Highly upregulated in liver cancer; NC: Normal control group; *HULC*: *HULC* over-expression plasmid group; *HULC*-siRNA: *HULC* low-expression plasmid group; *miRNA-372-3p*: *miRNA-372-3p* over-expression plasmid group; *miR-372-3p*-siRNA: *miR-372-3p* low-expression plasmid group; WT-*HULC*: *HULC* wild type luciferase reporter plasmid group; MUT-*HULC*: *HULC* mutant luciferase reporter plasmids group; WT-*Rab11a*: *Rab11a* wild type luciferase reporter plasmid group; MUT-*Rab11a*: *Rab11a* mutant luciferase reporter plasmids group.](WJG-25-5283-g005){#F5}

Rab11a is a direct target of miR-372-3p in HCC cells
----------------------------------------------------

Next, we used bioinformatic analyses to predict the downstream target of *miR-372-3p*. We identified *Rab11a* as a putative target of *miR-372-3p*. To validate the interaction between *miR-372-3p* and *Rab11a*, we performed luciferase reporter assays using plasmids with wild type *Rab11a* and mutated *Rab11a* (Figure [5D, 5E](#F5){ref-type="fig"}). Co-transfection of the luciferase reporter plasmid containing wild type *Rab11a* and *miR-372-3p* inhibitors in HCC cells led to increased luciferase activity (Figure [5E](#F5){ref-type="fig"}). Additionally, *miR-372-3p* inhibitors increased Rab11a expression (Figure [5F](#F5){ref-type="fig"}).

HULC acts via the miR-372-3p /Rab11a axis
-----------------------------------------

To further confirm whether *HULC* can regulate the secretion of exosomes *via* the *miR-372-3p*/Rab11a axis, *HULC*-siRNA and *miR-372-3p*-siRNA were co-transfected into HCC cells. We found that the expression of Rab11a was inhibited by *HULC* silencing, whereas *miR-372-3p* downregulation rescued Rab11a expression (Figure [6](#F6){ref-type="fig"}). Western blot assays showed similar results (Figure [6](#F6){ref-type="fig"}). These findings indicate that *HULC* can promote the secretion of exosomes by decreasing *miR-372-3p* and increasing Rab11a expression.

![Expression of Rab11a in hepatocellular carcinoma cells transfected with highly up-regulated in liver cancer-siRNA and *miR-372-3p*-siRNA. Silencing *HULC* inhibited Rab11a expression, while silencing *HULC* and *miR-372-3p* increased Rab11a expression *in vitro*. Error bars stand for the mean ± SD of at least triplicate experiments. ^a^*P* \< 0.05 *vs* NC group; ^b^*P* \< 0.05 *vs* NC group. *HULC*: Highly upregulated in liver cancer; NC: Normal control group; *HULC*-siRNA: *HULC* low-expression plasmid group; *miR-372-3p*-siRNA: *miR*-*372-3p* low-expression plasmid group.](WJG-25-5283-g006){#F6}

Increased HULC and Rab11a and decreased miR-372-3p promote secretion of exosomes from HCC cells
-----------------------------------------------------------------------------------------------

NTA was used to detect the expression of exosomes in the following groups. The number of exosomes from HepG2 and SMMC7721 cells in the *HULC* group was higher than that in the *HULC*-NC or NC group. However, there was no significant difference between the *HULC*-NC and NC groups (Figure [7A](#F7){ref-type="fig"}).

![Increased long non-coding RNA highly up-regulated in liver cancer and *Rab11a* and decreased *miR-372-3p* promote the secretion of exosomes from hepatocellular carcinoma cells. A: Quantification of exosomes after transfecting *HULC* over-expression plasmid into HCC cells; B: Quantification of exosomes after transfecting *miR-372-3p* low-expression plasmid into HCC cells; C: Quantification of exosomes after transfecting *Rab11a* over-expression plasmid into HCC cells. Error bars stand for the mean ± SD of at least triplicate experiments. ^a^*P* \< 0.01 *vs* NC group; ^b^*P* \< 0.01 *vs HULC*-NC group; ^c^*P* \< 0.01 *vs* NC group; ^d^*P* \< 0.01 *vs* miRNA-*372-3p-*siRNA-NC group; ^e^*P* \< 0.01 *vs* NC group; ^f^*P* \< 0.01 *vs Rab11a-NC* group. *HULC*: Highly upregulated in liver cancer; *HULC*: *HULC* over-expression group; *HULC*-NC: *HULC* (over-expression plasmid normal control group); NC: Normal control; *miR*-*372-3p-*siRNA: *miR*-*372-3p* low-expression group; *miR-372-3p-*siRNA-NC: *miR*-*372-3p* low-expression plasmid normal control group; *Rab11a*: *Rab11a* over-expression group; *Rab11a-NC*: *Rab11a* over-expression plasmid normal control group.](WJG-25-5283-g007){#F7}

The number of exosomes from HepG2 and SMMC7721 cells in the *miR-372-3p-siRNA* group was higher than that in the *miR-372-3p-siRNA*-NC or NC groups. However, there was no significant difference between the *miR-372-3p*-NC and NC groups (Figure [7B](#F7){ref-type="fig"}).

The number of exosomes from HepG2 and SMMC7721 cells in the *Rab11a* group was higher than that in the *Rab11a*-NC or NC groups. However, there was no significant difference between the *Rab11a*-NC and NC groups (Figure [7C](#F7){ref-type="fig"}).

DISCUSSION
==========

Many studies have reported that lncRNAs participate in various cellular processes and have key functions in cancer epigenetics. Specifically, some lncRNAs are associated with recurrence, metastasis, and prognosis of various cancers, such as HCC, gastric cancer, and breast cancer\[[@B19]-[@B22]\]. LncRNA *HULC* is one of them, playing an important role in the development of liver tumors. *HULC* is highly expressed in HCC and is involved in the regulation of tumorigenesis and development\[[@B5]\]. Phosphorylation of the cAMP response element binding protein (CREB) activates the transcription of HULC\[[@B16]\]. Du et al\[[@B23]\] found that the mechanism for hepatitis B virus X protein (HBx)-activated *HULC* to promote the proliferation of HCC cells is closely related to downregulation of p18. *HULC* mediates abnormal lipid metabolism in HCC cells by sequestering *miR-9*\[[@B24]\]. *HULC* is also expressed in gastric cancer\[[@B25]\], pancreatic cancer\[[@B26]\], and other cancers.

Our clinical data showed that *HULC* expression is increased in HCC tissues compared with adjacent liver tissues. Moreover, we found that *HULC* expression was higher in the exosomes derived from the serum of patients with HCC than in those derived from the serum of healthy controls. Notably, *HULC* expression in HCC tissues and serum exosomes was significantly related to HCC clinical stage. Therefore, *HULC* can be used as a potential biomarker candidate in HCC. Although *HULC* has been shown to participate in neoplasm invasion and metastasis, the underlying mechanism remains unclear. In recent years, the relation between exosomes and tumor progression has become evident\[[@B27]\]. However, the role of *HULC* in this process has not been demonstrated.

Exosomes play a key role in HCC progression\[[@B13]\]. Exosome-mediated miRNAs regulate TAK1 expression and lead to deterioration of HCC\[[@B28]\]. In addition, lncRNA *H19* in exosomes derived from CD90+ HCC cells influence tumor microenvironment balance by accelerating angiogenesis\[[@B29]\]. Exosome-mediated lysyl oxidase-like 4 (LOXL4) activation promotes tumor metastasis by modulating the *FAK/SRC* pathway in HCC\[[@B30]\]. Several studies have confirmed that lncRNAs in blood-circulating exosomes can be used as diagnostic markers for cancers: *LINC00152*\[[@B31]\] and *ZFAS1*\[[@B32]\] in gastric cancer, *MALAT-1*\[[@B33]\] in lung cancer, *BCAR4*\[[@B34]\] and *CRNDE-h*\[[@B35]\] in colon cancer, and *HOTAIR*\[[@B36]\] in laryngeal squamous cell carcinoma.

In this study, we showed that the expression of *HULC* in exosomes from HCC serum and in HCC tissues were higher than that in the control group, and that there was a linear correlation between them. Therefore, *HULC* in exosomes from the blood of patients with HCC can be used as a diagnostic marker. We showed that the expression of *HULC* in exosomes correlated with TNM stage and therefore, with the progression of HCC. These findings are in agreement with previous studies\[[@B5],[@B37]\].

We also investigated the relationship between *HULC* and exosome secretion. Bioinformatic analyses suggest that *HULC* mediated the secretion of exosomes from HCC cells *via* the *miR-372-3p/Rab11a* axis. Rab11a is a key regulatory protein that induces exosome secretion. In addition, we found that the number of exosomes from HCC cell lines overexpressing *HULC* was higher than that of control groups, indicating that *HULC* promotes exosome secretion.

Many studies have reported that lncRNAs act as sponges of miRNAs and inhibit their function\[[@B38]\]. For example, *HULC* mediates abnormal lipid metabolism in HCC cells by sequestering *miR-9*\[[@B24]\]. Here, we observed a negative correlation between *HULC* and *miR-372-3p*. A previous report showed that low *miR-372-3p* expression correlates with a poor prognosis and tumor metastasis in HCC\[[@B39]\]. Our results showed that when *HULC* was upregulated in HCC cells, *miR-372-3p* was repressed. Dual-luciferase reporter assays confirmed that *HULC* directly interacted with *miR-372-3p*. In addition, decreased levels of *miR-372-3p* promoted the secretion of exosomes from HCC cells.

Rab11a is a member of the subfamily of the Rab small molecule GTPases and is a key regulatory protein that induces exosome secretion\[[@B14],[@B15]\]. Rab11a plays an important role in the regulation of endosome recycling and is highly expressed in many tumors, such as esophageal adenocarcinoma\[[@B40]\] and skin cancer\[[@B41]\]. In addition, the Rab11 family-interacting protein 4 is involved in the metastasis of HCC\[[@B42]\]. In our study, we found that *Rab11a* is a downstream target of *miR-372-3p* and that it promotes the secretion of exosomes from HCC cells. Collectively, our results suggest that *HULC* negatively interferes with *miR-372-3p*-mediated inhibition of Rab11a, leading to secretion of exosomes in HCC.

In conclusion, we demonstrated that *HULC* enhances the secretion of exosomes by sponging *miR-372-3p* which in turn targets *Rab11a*. Our findings provide novel insights into the mechanism of action of *HULC* in HCC. We plan to continue investigating the precise mechanisms through which Rab11a and exosomes regulate HCC development. Whether *HULC* targets other miRNAs to promote exosome secretion also warrants additional research. In addition, we need to further explore the relationship between silencing of *HULC* and angiogenesis, epidermal mesenchymal transition, and lipid metabolism in HCC. Furthermore, the relationship between silencing of *HULC* and survival and prognosis of patients with HCC needs to be elucidated.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Long non-coding RNA highly up-regulated in liver cancer (lncRNA *HULC*) is highly expressed in hepatocellular carcinoma (HCC), and involved in the development and regulation of tumorigenesis. The relationship between *HULC* and exosomes has not yet been reported. Studying the mechanism of exosome secretion is helpful to reveal the pathogenesis of HCC.

Research motivation
-------------------

Although *HULC* has long been known to play important roles in HCC, its function and regulatory mechanism are unclear. Since exosomes participate in the progression of HCC, they have been actively studied. We are interested in exploring whether *HULC* regulates exosome secretion and is involved in the occurrence and development of hepatocellular carcinoma. This study will provide novel insights into the mechanism of action of *HULC* in HCC.

Research objectives
-------------------

The main objective of the study was to explore the molecular mechanism of *HULC* to regulate exosome secretion and and provide novel insights into the mechanism of action of *HULC* in HCC.

Research methods
----------------

We collected samples from serum and tissues of 30 patients with HCC. We measured *HULC* expression in the serum exosomes and liver cancer tissues of patients, and compared the data to those obtained from controls. We further explored the effect of *HULC* upregulation in HCC cell lines and studied the relationship between *HULC* and other RNAs using qPCR and dual-luciferase reporter assays. NTA was used to detect the quantity of exosomes.

Research results
----------------

*HULC* expression in serum exosomes of patients with HCC was higher than that in serum exosomes of healthy controls, and *HULC* levels were higher in liver cancer tissues than in adjacent tissues. The expression of *HULC* in serum exosomes and liver cancer tissues correlated with the tumor-node-metastasis (TNM) classification and *HULC* expression in tissues correlated with that in serum exosomes. *HULC* promoted HCC cell growth and invasion and repressed apoptosis. Additionly, it also facilitated the secretion of exosomes from HCC cells. Moreover, qPCR assays show that *HULC* repressed *microRNA-372-3p* (*miR-372-3p*) expression. We also identified Rab11a as a downstream target of *miR-372-3p*. Dual-luciferase reporter assays suggest that *miR-372-3p* could directly bind both *HULC* and Rab11a.

Research conclusions
--------------------

*HULC* regulates Rab11a to promote secretion of exosomes by competitive *miR-372-3p* sharing, and this finding provides new insights into the molecular mechanism to regulate the secretion of exosomes from HCC cells.

Research perspectives
---------------------

We aim to further explore the potential of serum exosome *HULC* as a sensitive preoperative marker for HCC and the role of *HULC* in the staging and prognosis evaluation of HCC.
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